Randomized clinical trials (RCTs) currently apply the same statistical threshold of alpha = 2.5% for controlling for false-positive results or type 1 error, regardless of the burden of disease or patient preferences. Is there an objective and systematic framework for designing RCTs that incorporates these considerations on a case-by-case basis?
T here is general agreement in the biomedical community that the development of therapies for certain diseases should take priority. This ethic has motivated legislative initiatives, such as the Orphan Drug Act of 1983, and underpins several important innovations in regulatory approval processes, such as the US Food and Drug Administration's (FDA) fast-track, breakthrough-therapy, accelerated-approval, and priority-review designations. 1 However, none of these innovations directly address the critical issue of how to incorporate the patient's perspective in deciding whether a drug candidate should be approved or not.
The current approach in clinical trial design is to minimize the chance of ineffective treatment caused by a type 1 error, that is, a false-positive result. However, the arbitrary nature of the threshold for the probability of type 1 error, alpha, raises an ethical question about its justification. A 2.5% threshold may not be appropriate for terminal illnesses that have no effective therapies; such patients may prefer to take a bigger chance on a false-positive result, even if the likelihood of an effective therapy is small. To quote the noted biostatistician Donald Berry, "We should also focus on patient values, not just P values." 2, 3 We propose to incorporate patient values and preferences into clinical trials in an objective, systematic, transparent, and repeatable manner using Bayesian decision analysis (BDA). This is a well-known quantitative framework for making the tradeoff between type 1 and type 2 errors, balancing the consequences of false-positive and false-negative errors on patients. While Bayesian methods have long been used in clinical trial design, 4-9 they are less popular in practice, in part because of the research community's inexperience with unfamiliar methods. 10 However, recently there has been renewed interest in the Bayesian approach, highlighted by the FDA's commitment to "facilitate the advancement and use of complex adaptive, Bayesian, and other novel clinical trial designs." 11 Motivated by these developments, we previously proposed a novel framework to calculate the optimal values of the alpha and power for randomized clinical trials (RCTs) that minimize the expected harm to patients, given the parameters relevant to any specific disease.
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Herein we apply this framework specifically to oncology therapeutics. The appropriate cost parameters and prior odds ratios 13 were first estimated for the 23 most common cancer sites in the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) database, and used to construct hypothetically optimal balanced 2-arm fixed-sample RCTs to minimize the average impact of both types of errors on patients. We then applied this framework to actual clinical trial data from 10 current phase 3 studies sponsored by the Alliance for Clinical Trials in Oncology (Alliance), an NCI-funded group that performs large national phase 2 and 3 clinical trials, and performed a similar analysis using various patient-appropriate endpoints. We find that the BDA-optimal design is often starkly different in size, power, and sample size from the traditional approach.
Methods
We considered a hypothetical new therapy, with a given hazard ratio assuming it is effective, to be tested in a balanced 2-arm fixed-sample RCT, where the endpoint is overall survival. To specify a fixed-sample RCT, we required 2 parameters: the number of participants in each arm of the study, n, and the probability of type 1 error, alpha, where the null hypothesis is the case where the drug is ineffective and possibly toxic (the power can be calculated using the sample size of the RCT, ie, n, and its alpha). The RCT search space for the optimal trial consists of all possible combinations of n and alpha with each pair of values defining a particular fixedsample RCT.
To define the potential harm or cost associated with a given RCT, we considered the 2 possible outcomes for the therapy: effective or ineffective. If the therapy is effective, the 2 costs associated with an RCT are: (1) the duration of the trial, when patients outside of the treatment arm are not receiving the therapy; and (2) the loss to all patients who could have benefited if this effective therapy is incorrectly rejected in the trial. If the therapy is ineffective and possibly harmful, the costs are: (1) the adverse effects of the therapy on patients in the treatment arm during the trial; and (2) the adverse effects on all patients who use this therapy if it is incorrectly approved. These costs depend on a number of auxiliary parameters-the degree and duration of health benefits for an effective therapy and the severity of adverse effects for an ineffective therapy-that can be estimated using epidemiological and clinical-trial data.
Once these costs have been estimated for each scenario, they were multiplied by the probability of each scenario and summed to yield an overall expected cost of the RCT-not to be confused with the financial costs associated with the RCTwhich is often called "Bayes risk" in decision theory. The objective of BDA is to compute the optimal sample size (n*) and type 1 error (alpha*) that jointly minimize the expected cost of the trial. In other words, we sought to conduct a trial that minimizes the average cost to patients-both in the trial and in the general population-where the average is taken over both possibilities of effective and ineffective therapies.
BDA-optimal trials can also be interpreted as trials that minimize the expected harm to patients, where harm is either: type 1 harm-an extra burden on patients owing to the adverse effects of the treatment in the case of a toxic and ineffective drug, caused by a false-positive result; or type 2 harm-a missed opportunity to reduce the burden of disease on patients owing to the length of the RCT (even if the drug is approved) and/or a rejection of an effective treatment in the RCT, caused by a false-negative result.
Type 2 harm is rarely discussed in medical and lay communities because it is difficult to quantify the number of missed opportunities, especially compared with the highly visible backlash created by incorrectly approving a toxic drug. However, missed opportunities to reduce the burden of disease on current and future patients, ie, type 2 harm, have real and quantifiable social costs, just as type 1 harm does. Unless these types of harm are properly balanced against each other, highly conservative drug approval processes may not be protecting all patients from harm. The primary objective of this article is to propose an objective method for balancing these harms explicitly.
Although the effectiveness and possible adverse effects of a drug are not precisely known at the time of the RCT design, it is still possible to list scenarios-both positive and negativethat the drug might face, along with their implications for patients. It is also possible to construct plausible estimates of the likelihood of each scenario using the information that the trial investigators and sponsors have at their disposal from previous clinical phases at the time of the RCT design. Therefore, not only is it practical to design a quantitative framework where the risks of a treatment are balanced against its benefits, it is also ethically necessary to ensure that both types of harm are accounted for when deciding whether a drug should be approved.
Results
The utility of BDA-optimal RCTs can be illustrated by applying the methodology to each of the 23 most common cancer sites based on estimated prevalence counts (prevalence proportions times US population estimates) listed in the NCI's SEER database.
14 For each cancer site, we determined the optimal balanced 2-arm fixed-sample RCT for testing a therapy that tar- Expected burden of disease in the extended months of life owing to taking effective treatment.
The same as the current average burden of disease (ie, its disability weight, 15 which ranges from 0, no loss of health, to 1, complete loss of health or death).
We assume the effective treatment only extends life and does not improve the health state of patients compared with their current health state.
Time until adverse effects of a toxic drug are discovered after it is mistakenly approved.
years
We assume that if a toxic drug is falsely approved, its adverse effects will be discovered 10 years after the approval and the drug will be taken off the markets. This is a conservative estimate. Follow-up period after enrolling the last patient.
Equal to the expected control group survival time.
After the last patient is enrolled, patients are followed up for this amount of time before any data analysis is conducted. This follow-up period is capped at 3 years.
Expected time until a new treatment is discovered for the disease that is at least as effective as the drug tested in the RCT.
On average, it takes this many years to get a drug, which is better than an effective treatment that is being tested in the RCT.
Maximum RCT power for the alternative hypothesis.
90%
This is a practical consideration in the design of RCTs.
Abbreviation: RCTs, randomized clinical trials. gets the late stage of the cancer, where the endpoint is overall survival. A complete list of assumptions on the RCT setting is provided in Table 1 . These are clearly hypothetical examples, because treatment for each cancer site is highly dependent on the stage and the patient (see the Supplement for the specific assumptions underlying the cost estimates and probabilities for types 1 and 2 errors). To allow the reader to verify the impact of specific assumptions, we have provided an easy-touse interactive tool in the Supplement that calculates the BDAoptimal RCT design for various input parameter values. The results are contained in Table 2 .
The entries in this table show that cancers with the worst prognoses, eg, cancers of the brain and pancreas, have relatively large BDA-optimal type 1 error rates (alpha) of 47.9% and 26.6%, respectively. Patients with terminal disease simply cannot afford to miss any effective drugs that can extend their lives by 11 months for brain cancer, and by 5 months for pancreatic cancer. These values differ greatly from the BDA-optimal type 1 error rates of breast cancer, colorectal cancer, and lymphomas-17.6%, 13.1%, and 12.2 to 12.8%, respectively. The prognosis for this set of cancers is considerably more optimistic than that of the former set, even for patients with late-stage disease. It is worth noting, however, that in all cases the type 1 error rates recommended by the BDA far exceed the traditional standard of 1-sided alpha, namely, 2.5%. Finally, although there is, in general, little variation in optimal type 2 error rates, in cancers with the best prognosis, Hodgkin lymphoma and cancer of the testis, the recommended power is well below 90%, owing to the need to keep the trial duration short to avoid exposing too many patients to inferior medications in the treatment arms of these trials.
A sensitivity analysis is provided in the Supplement to investigate the robustness of these results to perturbations in our model's key parameters. We found that cancers with poor prognoses consistently had relatively large BDA-optimal type 1 error rates and small optimal RCT sample sizes. Our observation that a patient with a poor prognosis cannot afford to miss any effective drugs-even in the face of greater risk of falsepositive results-is robust over a wide range of parameters. Moreover, all the type 1 error rates recommended by the BDA analysis remain far in excess of the traditional 2.5% 1-sided alpha. However, the specific critical value and sample size of each optimal RCT is sensitive to the underlying assumptions. For example, a 15% increase in the a priori probability of an ineffective therapy from 65% to 80% leads to a more conservative trial design, reducing the optimal alpha for brain cancer RCTs from 48% to 19% and increasing the optimal sample size from 152 to 268. Conversely, decreasing either the pa- tient accrual rate or the toxic effects of an ineffective therapy leads to less conservative (ie, larger alpha and smaller sample size) RCT designs. Intuitively, decreasing the patient accrual rate increases the trial length, and for patients with short life expectancies, the optimal tradeoff involves maintaining a relatively short trial length. Similarly, decreasing the toxic effects of an ineffective drug under the null hypothesis reduces the cost of a more aggressive RCT design. When taken to the limit of no toxic effectsclearly an unrealistic assumption-the optimal RCT design becomes extremely aggressive and the protocol approves the majority of investigational drugs after minimal clinical trial study. In this case, there are few benefits gained by rejecting an ineffective drug, mitigating the tradeoff central to the expected cost optimization. Note that a nontoxic therapy in this model is one that is equally as effective as the standard treatment, and therefore should be considered a limiting case. This example highlights the need for carefully considered assumptions and accurately calibrated cost models when implementing the BDA-framework (Supplement).
A practical illustration of the BDA methodology can be obtained using actual clinical-trial data from the Alliance portfolio to compute BDA-optimal RCTs for 10 of the phase 3 clinical trials currently actively enrolling or following patients, and comparing the results with the current designs of the Alliance trials.
The results are presented in Table 3 , where the last 3 columns characterize the BDA-optimal RCT for each cancer site, arranged by rows. The features of BDA-optimal RCTs are summarized in Figure 1 and Figure 2 , which show substantial departures from the comparable parameters of the Alliance trials, especially for high-mortality and low-prevalence cancers.
The differences between traditional and BDA-optimal RCTs are especially striking in 4 rows of Table 3 : glioblastoma (row 1); castration-resistant metastatic prostate cancer (row 4); stage III colon cancer (row 8); and early-stage prostate cancer (clinical stage ≤T2a, row 10).
For glioblastoma (GBM), there was a stark contrast between the conventionally designed current RCT and the BDAoptimal RCT. The sample size for the conventional RCT was 400 patients, while the BDA-optimal sample size was 104, a 74% reduction. Moreover, the type 1 error rate for the BDAoptimal trial was 47.5%, much larger than the standard 2.5% 1-sided type 1 error rate set in the traditional RCT (in fact, the Alliance trial used twice the standard 2.5% type 1 error in recognition of the limited population and poor prognosis of GBM patients).
The smaller number of patients and larger alpha in the BDAoptimal trial were more permissive than the comparable values for traditional RCTs so as to reduce type 2 harm. The decrease in type 2 harm was large enough to offset the excess risk resulting from the extra permissiveness in the trial, and the overall penalty-the expected harm to current and future patients-was minimized under the BDA-optimal RCT.
For castration-resistant metastatic prostate cancer, we also observed a clear difference between the traditional and BDAoptimal RCTs. The sample size of the BDA-optimal RCT was only 55% of the sample size for the traditional RCT, 676 vs 1224 patients, and the type 1 error rate for the BDA-optimal trial was 16 and the traditional and BDA-optimal RCTs were almost equivalent, with sample sizes of 2500 vs 2232, and type 1 error rates of 2.5% vs 2.3%, respectively. Finally, for early-stage prostate cancer (clinical stage ≤T2a) therapies, the BDA-optimal RCT was more conservative than the current Alliance RCT. The BDA-optimal RCT was slightly smaller than the traditional RCT, 418 vs 464 patients, while allowing a much smaller chance for falsepositive results-0.9% vs 2.5% in the conventional RCT. In this case, the harm from approving an ineffective therapy was considerably more serious than rejecting an effective one because the burden of disease was relatively less severe while the adverse effects of an ineffective therapy would impact a large number of patients, hence the more conservative BDA-optimal parameters.
Limitations
Our findings must be qualified in several respects. First, we have considered only traditional fixed-sample RCTs; in practice, adaptive trial designs may include an interim analysis for early signals of efficacy, futility, or toxic effects, or may be adaptive in other ways. Any of these possible adaptations in any given trial may alter the optimal type 1 and 2 error rates and appropriate modifications to our calculations are required to determine the optimal designs for these settings.
Second, the trials considered here use the overall survival endpoint, which is clear and of unambiguous importance. However, for a variety of reasons, many trials use alternative endpoints, such as progression-free survival, the clinical relevance of which is less clear. Study-specific definitions of type 1 and 2 harm would require greater subtlety in trials with endpoints other than overall survival. Third, owing to recent advances in cancer biology and a better understanding of cancer molecular profiles, it is clear that cancer-even within a single site-refers to a collection of heterogeneous diseases with different molecular and genetic profiles. Our framework can be readily adapted to subdiseases within each of these cancers, provided that relatively accurate information on the burden of these subdiseases and their survival statistics, prevalence, incidence, and death rates are available.
Fourth, even though type 1 errors like 47.5% for GBM may be optimal for terminal illnesses with no existing treatments, they could inadvertently encourage the development of marginal therapies. This adverse incentive can be addressed by asking the FDA to create a new class of experimental therapeutics that have fixed terms of contingent approval, contingent on stringent postapproval monitoring where more data will be collected and analyzed. If the new data confirm the therapy's efficacy, the contingent approval status can be converted to unconditional approval, otherwise the contingent approval expires.
Finally, we have confined our attention to patients' medical outcomes without considering the cost to patients and their families, to industry, or to society. New therapeutic agents often come at a very high financial cost, which, when taken into account, may raise the bar of success for new agents, thus lowering the acceptable type 1 error rate. On the other hand, the increased type 1 error rates that we have proposed may lower the cost of clinical trials and reduce the risk to sponsors, which may encourage drug development, lower drug costs, and further accelerate clinical research. To incorporate perspectives from the entire biomedical ecosystem, as well as the value of patient input to the drug development process, we have proposed that the FDA form a patient advisory board consisting of key stakeholder groups-patients, caregivers, physicians, biopharma executives, regulators, and policymakers-with the specific charge of formulating explicit cost estimates for type 1 and type 2 errors. These estimates can then be incorporated into the FDA decision-making process as additional inputs to their quantitative and qualitative deliberations.
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Conclusions
Traditional RCTs do not necessarily minimize overall harm to current and future patients, especially for life-threatening cancers that currently have no effective therapies. In these cases, traditional RCTs are too lengthy, too conservative, and focused too much on rejecting ineffective drugs and avoiding false-positive results. This single-minded focus can result in missed opportunities to treat life-threatening conditions, which can sometimes harm more patients than mistakenly approving ineffective and possibly toxic drugs.
Conversely, for some less aggressive cancers, such as earlystage prostate cancer, the current thresholds of statistical significance are more permissive than the BDA-optimal thresholds. In these cases, traditional RCTs allow a larger chance of falsely approving ineffective and possibly toxic drugs, risking patients' health even though the potential benefits from these trials do not necessarily justify the risk.
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Expected RCT Penalty
In this section, we formulate the expected penalty associated with a fixed-sample balanced two-arm randomized clinical trial (RCT) that involves cancer therapeutics. Let be the cost for a given fixedsample test with patients in each arm and a critical value . Assuming prior probabilities and = 1 for the null ( toxic drug) and alternative ( effective drug) hypotheses, respectively, the expected cost is given by
If we further assume exponential distributions for the time to event (death) for each patient given a particular treatment, and for the time until an at least equally effective therapy is discovered, then the conditional expectations in (1) can be decomposed into two components: the expected cost per person given an inferior treatment, and the expected number of patients who receive an inferior treatment. The cost factors can be formulated as two constants, and , which represent the expected cost per person of being treated with the toxic drug given the null hypothesis, and the expected cost per person of not being treated with an effective drug given the alternative hypothesis, respectively,
where denotes the life expectancy of patients under the standard treatment, tox is the life expectancy given a toxic drug, eff is the life expectancy given an effective drug, is the burden of disease, tox is the burden of disease given a toxic drug, and eff is the burden of disease given an effective drug. Intuitively, (2) states that the expected cost of being treated with the toxic drug relative to the standard treatment consists of a deteriorated condition over time tox , and a complete loss of life over time tox . Similarly, (3) states that the expected cost of foregoing the effective drug for the standard treatment is the missed opportunity of an improved condition over time , and a disability weighted life extension over time eff . Note that in our paper we assumed an effective drug only increases life expectancy, and does not improve the patient's current conditions (i.e., = eff ). Now consider the expected number of patients who receive the toxic drug under the null hypothesis. We denote , , and as the expected number of current patients, patients diagnosed during the trial period, and patients diagnosed after the trial period who receive the toxic drug given a type I error, respectively. Defining , , and to be the start-up time before patient enrollment, the follow-up period after enrolling the last patient, and the patient accrual period (i.e., the inverse of the accrual rate), respectively, and assuming uniform (evenly spaced) patient enrollment, the length of the trial period can be calculated as = + + 2 . Given a type I error, a current patient will receive the toxic drug if the patient lives beyond the trial period (probability exp( / ), where exp(·) is the exponential function), and a new treatment is not discovered before the end of the trial (probability exp( / ), where is the expected time until an alternative effective therapy is discovered). Assuming these are independent events,
where is the disease stage-specific prevalence. Similarly, a patient diagnosed with the disease during the trial phase at time will receive the toxic drug if the patient lives beyond the trial period (probability exp( ( )/ )), and a new therapy is not discovered before the end of the trial. Given an incidence rate ,
Finally, a patient diagnosed with the disease after the trial phase at time will receive the toxic drug if a new treatment has not yet been discovered, and the drug has not yet been taken off the markets. Assuming the time until the adverse effects of the toxic drug are discovered after it is mistakenly approved is given by ,
Since the sample size is fixed, we find that in-trial patients always receive the toxic drug, and therefore the expected cost under the null hypothesis is given by
where ( ) is the probability the drug is approved ( is the cumulative distribution function of a standard normal random variable).
In a similar fashion, we now consider the alternative hypothesis, and the expected number of patients who do not receive the effective drug and die before an alternative therapy is discovered. We denote as the expected number of patients who satisfy this criterion given a type II error. In the case where the effective drug is mistakenly rejected, any patient diagnosed with the disease before an alternative therapy is discovered will miss the opportunity to take the effective drug, and therefore
where /( + ) is the probability that the patient dies before an alternative effective therapy is discovered. Even when the drug is correctly approved, a number of patients will not receive the effective drug and die before an alternative therapy is found because of the trial's delay. Specifically, a current patient would be negatively affected by the delay if either an alternative therapy was developed before the end of the trial period and they died before this alternative therapy was released, or an alternative therapy was not developed by the end of the trial period, and they died before the trial's effective drug was released. The expected number of current patients affected by the delay given no type II error, , is then
Similarly, a patient diagnosed with the disease during the trial phase at time t would be negatively affected by the delay if they died before an alternative therapy was discovered, and either this alternative therapy was developed after time t and before the end of the trial, or they died before the end of the trial period. The expected number of future patients affected by the delay given no type II error, , can then be formulated as
Collecting terms, the expected cost under the alternative hypothesis is given by
where ( ) is the probability of a type II error, and is the mean of the log-rank statistic in the Cox Proportional Hazard regression under the alternative hypothesis. We have the following expression for :
where denotes the hazard ratio, / eff , and , is the probability that a subject in trial arm will suffer an event (death) during the observation period. Subjects in the control arm ( = 0) have a shorter life expectancy than subjects in the experimental arm ( = 1) who receive the effective drug. Therefore , where , = + 2 is the observation period for subject in trial arm .
Assumptions Underlying Hypothetical BDA-Optimal RCTs for 23 Cancer Sites
In the control arm of the study, patients are administered the standard of care for the late stage of the specific cancer, whereas an investigational drug is administered to the patients in the treatment arm. We assume that the enrolled patients are randomized to either arm with equal probability, and the patients' enrollments in the RCT are uniformly spread across an enrollment period. The duration of the enrollment period is determined by the patient accrual rate for each cancer type, which increases linearly with the U.S. prevalence of the distant stage of the cancer, and is bounded between 100 and 800 patients per year for all the studied cancer sites. We further assume that the time required for the study setup before the first patient enrollment is 1 year, and that the time between the enrollment of the last patient and the final data analysis is set to either the expected survival time of the patients in the control arm or 3 years, whichever is lower.
Hence, the follow-up time for patients who enroll in the RCT earlier is longer compared to the patients who enroll at a later time in the enrollment period. We assume that the Cox proportional hazards model is used to analyze the time-to-event data at the time of analysis.
Assume there is a 35/65 chance for the investigational drug to be effective or ineffective and toxic, respectively (this prior distribution is based on historical averages 14, 15 ). Note that baseline statistics and pretrial information for a given cancer site and therapy can be used to further calibrate these parameters. We analyze the robustness of our results to this and other key model parameters in the next section.
If the drug is effective, it is assumed to extend the patient's life by 30% of the expected survival time for patients with the distant stage of the cancer-or equivalently, a hazard ratio of 76.9% denoting the alternative hypothesis. To avoid extremely long survival extensions, we limit the gain in survival due to the effective drug to 2.5 years (30 months). We also assume that patients in this extended time before their death will experience the average disease burden that patients currently experience due to each cancer in the U.S. In other words, if the drug is effective, it only increases a patient's life by a certain number of months, and it does not improve the state of health of patients before death.
If the drug is ineffective, it is assumed to shorten each patient's life by 2 months on average, and to have side effects with a burden of 6.3% per year, the estimated average burden of disease associated with the adverse effects of medical treatments in the U.S. Burden of Disease Study 2010. 16 This level of burden means that each patient experiencing side effects would be indifferent to living each year with the side effects, or to losing 6.3% of each year (about 23 days) if, for the rest of that year, they could live without the side effects. We assume the worst-case scenario for the side effects; i.e., the adverse effects are persistent until the patient's death, and there will be no treatment to alleviate these side effects.
We assume that within each cancer type, at each point in time, there is an expected 10-year period before a drug at least as effective as the assumed investigational agent is discovered. More precisely, we assume an exponential distribution with a mean of 10 years for the time until a new, equally effective or better drug is discovered for each cancer site. We also assume that if a toxic drug is incorrectly approved, its side effects will be discovered 10 years after the approval, and that the approved drug will then be taken off markets. This is a relatively conservative assumption, since dangerous side effects are often discovered significantly more quickly in practice. Finally, we assume that due to practical considerations, the power of the trial is always maintained at or below 90%. For a complete list of assumptions on the RCT setting, refer to Table 1 . A full derivation of our expected cost model is provided in Section 1 of this Supplement.
Sensitivity Analysis
In this section, we investigate the robustness of our results to the underlying assumptions in our model. For each of the 23 cancer sites in our study, we determine the optimal balanced two-arm fixed-sample RCT for testing a therapy targeting the late stage of the cancer, where the endpoint is overall survival. We then vary the patient accrual rate, the a-priori probability of an effective therapy, and the toxicity of an ineffective drug about their proposed values, and obtain new optimal fixed-sample RCT designs for each value. The optimal and sample size values associated with the perturbed parameters are shown in Figures 1-8 .
In general, we find that cancers with poor prognoses consistently have relatively large BDAoptimal type I error rates ( ), and small optimal RCT sample sizes. Our observation that a patient with a poor prognosis cannot afford to miss any effective drugs, even at the expense of assuming substantial risks, is therefore robust over a wide range of conditions. Moreover, all the type I error rates recommended by the BDA analysis remain far in excess of the traditional 2.5% one-sided . However, the specific critical value and sample size of each optimal RCT is quite sensitive to the underlying assumptions. For example, a 15% decrease in the a-priori probability of an effective therapy from 35% to 20% reduces the optimal value for brain cancer RCTs from 48% to 19%, and increases the optimal sample size 76% from 152 to 268 (see Figures 3-4) . Conversely, decreasing either the patient accrual rate, or the toxicity of an ineffective therapy leads to less conservative-i.e., larger , and smaller sample size-RCT designs (see Figures 1-2 , and 5-8). Intuitively, decreasing the patient accrual rate increases the trial length, and for patients with short life expectancies, the optimal trade-off attempts to retain a relatively short trial length. Similarly, decreasing the toxicity of an ineffective drug under the null hypothesis reduces the cost of a more aggressive RCT design.
This final observation, when taken to its limit, affects the BDA-optimal RCT design substantially. Specifically, if either tox or tox are set to 0% or 0 months, respectively, then the BDA-optimal RCT design becomes extremely aggressive and the protocol approves the majority of investigational drugs after minimal clinical trial study. In this case, there are few benefits gained by rejecting an ineffective drug, eFigure 4. Sensitivity of the BDA-optimal sample size to the probability that the investigational drug is effective ( ) for the 23 most common cancer sites in the U.S. From the lower to upper end of each box plot, the five-number summary corresponds to = [50%, 42.5%, 35%, 27.5%, 20%]. A lower limit of 40 is applied to the sample size to ensure the log-rank statistic is approximately standard normal. eFigure 5. Sensitivity of the BDA-optimal 1-sided to the side effect level of burden of an ineffective drug ( tox ) under the null hypothesis for the 23 most common cancer sites in the U.S. From the lower to upper end of each box plot, the five-number summary corresponds to tox = [12.6%, 9.45%, 6.3%, 3.15%, 0%], where a 6.3% burden means that each patient experiencing side effects would be indifferent to living each year with the side effects, or to losing 6.3% of each year (about 23 days) if, for the rest of that year, they could live without the side effects. eFigure 6. Sensitivity of the BDA-optimal sample size to the side effect level of burden of an ineffective drug ( tox ) under the null hypothesis for the 23 most common cancer sites in the U.S. From the lower to upper end of each box plot, the five-number summary corresponds to tox = [0%, 3.15%, 6.3%, 9.45%, 12.6%], where a 6.3% burden means that each patient experiencing side effects would be indifferent to living each year with the side effects, or to losing 6.3% of each year (about 23 days) if, for the rest of that year, they could live without the side effects. A lower limit of 40 is applied to the sample size to ensure the log-rank statistic is approximately standard normal.
